SABCS 2018 — Delayed ACT linked to increased mortality in TNBC


  • Tara Haelle
  • Univadis
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Longer delays in administering adjuvant chemotherapy after surgery were associated with worse survival in women with triple-negative breast cancer (TNBC).

Why this matters

  • Receiving chemotherapy too soon after surgery can increase toxicity and adverse events. 

Study design

  • Retrospective analysis of survival of 687 women with stage I, II, or III TNBC, based on time to chemotherapy (TTC) between surgery and first dose of chemotherapy.
  • Population treated between 2000 and 2014 at the Instituto Nacional de Enfermedades Neoplasicas in Lima, Peru.
  • No disclosures. 

Key Results

  • TTC was classified as ≤30 days (27.5%), 31-60 days (47.9%), 61-90 days (16.7%), and ≥91 days (7.9%).
  • 10-year OS with TTC ≤30 days was 82.0% vs 67.4%, 67.1%, and 65.1% with TTC of 31-60, 61-90, and ≥91 days, respectively (P=.003).
  • 10-year disease-free survival was 81.4% with TTC ≤30 days vs 68.6%, 70.8%, and 68.1% TTC of 31-60, 61-90, and ≥91 days, respectively (P=.005).
  • 10-year distant recurrence-free survival was 80.2% with TTC ≤30 days vs 64.9%, 67.5%, and 58.6% with TTC of 31-60, 61-90, and ≥91 days, respectively (P<.001>
  • Compared with TTC ≤30 days, HR for mortality was 1.89 (P=.001), 2.16 (P=.001), and 2.41 (P=.002) at TTC of 31-60, 61-90, and ≥91 days.

Limitations 

  • Retrospective analysis.